Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gluten-free/casein-free diet and anti-inflammatory bowel therapy in children with autism and gastrointestinal symptoms
2009-012102-39Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Jul 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Salcrozine, beclomethasone, azathioprine and mercaptopurine in Autism Spectrum Disorder (ASD) and inflammatory bowel disease (IBD), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoints: Change in autism-related behavioral ratings and Change in inflammatory bowel disease/intestinal symptoms. Started Jul 2009; status: active.
02
Drugs
Salcrozinebeclomethasoneazathioprinemercaptopurine
03
Conditions
Autism Spectrum Disorder (ASD)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2009-012102-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012102-39.